跳至主要内容
临床试验/NL-OMON34971
NL-OMON34971已完成不适用

Role of hypercoagulability and hypofibrinolysis in the progression of hepatic fibrosis - Coagulation and Fibrosis

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 292 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
292

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. All participants of the Rotterdam Study (cohorts RS I-5, RS II-3 and RS III-1).
  • - 1a. TE values >12,5 kPa in the absence of steatosis will be considered as presence of advanced fibrosis. TE values >10,5 kPa in the presence of steatosis will be considered as presence of advanced fibrosis (cases).
  • - 1b. TE values < 5 kPa will be considered as absence of fibrosis or presence of mild fibrosis (controls)
  • 2. Male or female, age >=18
  • 3. All subjects must have provided written informed consent.

排除标准

  • a. Subjects with unreliable Fibroscan and/or US-examination, as evaluated by the executing technician.
  • b. No informed consent
  • c. Subjects with decompensated cirrhosis

研究者

相似试验

Role of hypercoagulability and hypofibrinolysis in... | 临床试验